| Name | Title | Contact Details |
|---|
John's Hopkins Healthcare LLC is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RemedyMD is the leading provider of registries for life sciences. RemedyMDs highly specific patient and disease registry software and comparative effectiveness research tools enable researchers, clinicians and scientists to collect, aggregate, harmonize, and analyze data from widely disparate sources and then use RemedyMD tools and applications to identify patterns that result in accelerated discoveries, better patient outcomes, and advance translational research.
MedeAnalytics provides evidence-based insights to solve a real problem that plagues health care – how to use the immense amount of patient data collected along the care continuum to deliver cost – effective care and promote a healthier population. The platform delivers intelligence that helps healthcare organizations detect their greatest areas of risk and identify opportunities to improve their financial health. It empowers providers and health plans to collaborate and use data to strengthen their operations and improve the quality of care. MedeAnalytics` cloud-based tools have been used to analyze more than 21 billion patient encounters in the United States and United Kingdom, providing better care to more than 30 million patients and better business for 900 healthcare organizations.
County Medical Services Program is a Sacramento, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.